Clinical Challenges: Test Your Knowledge on Recent Advances in DLBCL

Knowledge about the biology of diffuse large B-cell lymphoma (DLBCL) and the number of treatments approved for the disease continues to grow.

This three-question quiz will test one aspect from each article in MedPage Today‘s Clinical Challenges series on DLBCL that covered the following: use of bispecific antibodies versus CAR T-cell therapy in the relapsed/refractory disease setting; adoption of the first-line regimen of polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP); and the prophylaxis and treatment of central nervous system (CNS) relapse.

Correct answers and explanations appear after completing the quiz.

Leah Lawrence is a freelance health writer and editor based in Delaware.

Education and community exposure can increase breastfeeding rates in rural areas, study finds

While formula-feeding babies is a safe and convenient option, research studies have shown natural breastfeeding is linked to numerous health benefits for both mother and

July 4, 2023

FDA’s latest reorganization puts a new emphasis on its investigations

Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us

November 15, 2023

Mundipharma to acquire rezafungin assets from Cidara Therapeutics

Share this article Rezafungin is a once-weekly echinocandin intended for the treatment of invasive candidiasis in adults. Credit: nuiza11 via Shutterstock. Mundipharma has signed an

April 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.